Exploration of New Contrasts, Targets, and MR Imaging and Spectroscopy Techniques for Neuromuscular Disease - A Workshop Report of Working Group 3 of the Biomedicine and Molecular Biosciences COST Action BM1304 MYO-MRI
- Strijkers, G.J.
- Araujo, E.C.A.
- Azzabou, N.
- Bendahan, D.
- Blamire, A.
- Burakiewicz, J.
- Carlier, P.G.
- Damon, B.
- Deligianni, X.
- Froeling, M.
- Heerschap, A.
- Hollingsworth, K.G.
- Hooijmans, M.T.
- Karampinos, D.C.
- Loudos, G.
- Madelin, G.
- Marty, B.
- Nagel, A.M.
- Nederveen, A.J.
- Nelissen, J.L.
- Santini, F.
- Scheidegger, O.
- Schick, F.
- Sinclair, C.
- Sinkus, R.
- Sousa, P.L. de
- Straub, V.
- Walter, G.
- Kan, H.E.
DOIAbstract
Neuromuscular diseases are characterized by progressive muscle degeneration and muscle weakness resulting in functional disabilities. While each of these diseases is individually rare, they are common as a group, and a large majority lacks effective treatment with fully market approved drugs. Magnetic resonance imaging and spectroscopy techniques (MRI and MRS) are showing increasing promise as an outcome measure in clinical trials for these diseases. In 2013, the European Union funded the COST (co-operation in science and technology) action BM1304 called MYO-MRI (www.myo-mri.eu), with the overall aim to advance novel MRI and MRS techniques for both diagnosis and quantitative monitoring of neuromuscular diseases through sharing of expertise ...
Add to ORKG